Seeking Alpha
10 Nov 2026, 21:50 UTC · 19h ago
Biodesix, Inc. (BDSX) Presents at 2026 UBS Global Healthcare Conference Transcript
Impact · against what's priced in
The presentation highlights a potentially larger total addressable market for the Nodify tool than previously estimated. While the news is positive regarding the opportunity size, the transcript contains no specific new data on adoption rates or financial milestones to act as a near-term catalyst.
- BDSX+0.10
No priced-in read yet
- In context
Management suggests the total addressable market for the Nodify blood-based nodule risk assessment tool is larger than the 1.6 million annual U.S. patients previously cited, indicating a broader growth runway.
Read from the article alone
Search tags
